Genomtec S.A. received from the German company Dennemeyer Consulting GmbH a valuation of the Company’s intellectual property portfolio. According to the DIN/ISO 77100 standard adopted by Dennemeyer, covering 9 patents held by Genomtec and 26 patent applications, as well as the conversion of all patent applications into patents, as well as a 14-year protection period for the entire IP (intellectual property) portfolio, the fair value of Genomtec’s intellectual property was estimated at EUR 191.336 million.
Dennemeyer Consulting GmbH, adopting a conservative, only 8-year patent protection period, valued the Company’s portfolio of intellectual property rights at EUR 95.663 million. This valuation assumes a discount on patent applications currently being processed, and if the current 100% success rate of conversion of patent applications into patents is maintained, this value will increase to EUR 109.335 million. The average term of patent protection of Genomtec’s petitioners is over 15 years.
– In our opinion, the valuation of the Genomtec intellectual property rights portfolio estimated by Dennemeyer corresponds to its fair value. We currently hold 9 patents in Europe, USA and Japan and over 26 patent pending applications in global markets. Our portfolio of patents and patent applications is young and gradually growing. It should also be remembered that the presented valuation concerns only intellectual property and does not take into account aspects such as manufactured products, technical diagrams, Team, received certificates and admission to trading – said Miron Tokarski, CEO and Co-founder of Genomtec S.A. – Together with our transaction advisor Clairfield Partners LLC, we continue the process of establishing strategic partnerships, selling licenses and/or selling all or part of Genomtec’s intellectual property – said CEO.
Dennemeyer is a renowned global provider of legal services for patents, trademarks, data verification, project execution, litigation support audits, and other intellectual property portfolio management services. Dennemeyer is an entity with more than 60 years of tradition and 20 regional offices located on 6 continents, cooperating with entities such as Airbus, L’oreal, Boehringer Ingelheim and Gedeon Richter.
As part of Genomtec’s review of strategic options on November 30, 2022. The company has signed an agreement with Clairfield Partners LLC based in New York. The subject of the agreement is consultancy in the process of establishing a strategic partnership, selling licenses and/or selling all or part of the intellectual property and related technology. Clairfield has extensive experience in M&A transactions in the area of medical technology and biotechnology, including genetic diagnostics.